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Abstract
We have recently identified transcription factors (TFs) that are key drivers of breast cancer
risk. To better understand the pathways or sub-networks in which these TFs mediate their
function we sought to identify upstream modulators of their activity. We applied the MINDy
(Modulator Inference by Network Dynamics) algorithm to four TFs (ESR1, FOXA1, GATA3
and SPDEF) that are key drivers of estrogen receptor-positive (ER+) breast cancer risk, as
well as cancer progression. Our computational analysis identified over 500 potential modu-
lators. We assayed 189 of these and identified 55 genes with functional characteristics that
were consistent with a role as TF modulators. In the future, the identified modulators may be
tested as potential therapeutic targets, able to alter the activity of TFs that are critical in the
development of breast cancer.
Introduction
Modulator Inference by Network Dynamics (MINDy) is a gene expression profile-based
method to identify genes that modulate the transcriptional programme of a given transcription
factor (TF). That is, MINDy is able to systematically identify genes that encode proteins that
affect a TF’s activity without affecting its mRNA abundance. Modulators may act on the trans-
lation efficiency of the mRNA into protein, post-translationally modify the TF, affect the cellu-
lar localisation or turnover of the TF, form a transcriptional complex with the TF thereby
changing its activity, or compete for its DNA binding site. The MINDy algorithm was intro-
duced by the lab of Andrea Califano [1] and has been used to identify post-transcriptional
modulators of TF activity in human B-cells [2]. Briefly, the MINDy algorithm interrogates a
large gene expression profile dataset in order to identify candidate modulator genes able to
alter the relationship between a TF and its regulon (set of target genes). For each TF of interest,
a candidate modulator is tested by MINDy. Gene expression profiles from each of a set of
samples (here, individual tumours) are ranked by the expression of the selected modulator,
M (Fig 1). Sets of samples with high and low expression of the modulator are then selected
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(M-high and M-low). In each of the two sample sets, samples are then sorted according to TF
expression and the extent of correlation in gene expression between the TF and its target genes
is assessed. If the pattern of correlation differs significantly between M-high and M-low, then
M is a modulator of the activity of that TF. The analysis also tests whether the modulator is a
positive or negative one [1].
Here, we use the MINDy algorithm to identify modulators of the TFs ESR1, FOXA1,
GATA3 and SPDEF (Fig 1). Each of these is an important driver of estrogen receptor-positive
(ER+) breast cancer. In addition, these TFs are the master regulators (MRs) of the FGFR2
response, which is strongly associated with risk of breast cancer development [3,4]. ESR1,
GATA3 and FOXA1 form part of the well-characterised estrogen receptor transcriptional net-
work in ER+ breast cancer cells [5,6]. SPDEF is a novel co-regulator of the ESR1 transcriptional
network. SPDEF is normally expressed in a range of epithelial cell types, especially in hor-
mone-regulated tissues [7], and has been associated with cancer: SPDEF is overexpressed in
breast cancer cells [8–10] but is often lost in high-grade, invasive tumours [11]. It was origi-
nally identified as a co-factor of the androgen receptor [12].
Having identified potential modulators of these TFs in ER+ breast cancer, we validate the




Modulators of transcription factor (TF) activity are assessed by conditional mutual informa-
tion analysis as described elsewhere [1,2]. Briefly, this method takes a list of potential modula-
tors and computes the conditional mutual information over the TF-target interactions of a
given regulon. For each TF, the method measures the change in the mutual information
between the TF and its targets conditioned to the gene expression of the modulator. The list of
candidate modulators includes all genes annotated in the gene expression data, applying a
modulator independence constraint to each test in order to exclude those candidates that are
themselves correlated with the expression of the TF. The modulator inference was performed
in R using the tni.conditional function in the RTN package (http://bioconductor.org/packages/
RTN/) with 1000 permutations. The analysis pipeline has three main steps: (1) compute a reg-
ulatory network to derive regulons; (2) re-compute all regulons conditioned on the knowledge
of a given candidate modulator. This is the MINDy algorithm, which tests whether the TF-tar-
get mutual information changes conditioned on the presence/absence of the modulator (it
computes the differential mutual information). Here we also use a bootstrap analysis to check
the stability of the inferred modulated targets, that is, we check the frequency that the inferred
modulated targets can be observed in different subsamples; and (3) test whether the number of
modulated targets is greater than would be expected by chance using FET (Fisher’s Exact Test)
statistics. This step also tests the association between the observed modulated targets and the
TF-target strength using KS (Kolmogorov-Smirnov) statistics, which aims to check whether
the modulation happens in the strongest TF-target interactions. As a cut-off we chose an
adjusted P-value of<0.001. To generate Fig 1, MI was calculated to generate grey dots. The
shift from the original is calculated as dMI, which is scaled so that values are comparable across
all targets:
dMI ¼ ðMItop   MIbottomÞ=ðMItop þMIbottomÞ
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Fig 1. The MINDy algorithm. (A) Graphic representation of the MINDy analysis. For each tumour, gene expression activity is
calculated for a given transcription factor (TF), a TF target (t) and a possible modulator (M), and represented as a vertical,
coloured bar. Tumours are ranked by the expression value of the modulator. For the top 1/3 and bottom 1/3 of all tumours,
samples are re-ranked by TF expression and mutual information (MI) between the TF and target is calculated. If similar MIs are
obtained between the two groups no modulator activity is detected. However, if the MI value between the two groups is different,
M has modulator activity. (B and C) Schematics and overall results for two predicted FOXA1 modulators, ALDH3B and
ARHGEF2. The plots show the distribution of MI for the entire set of FOXA1 targets. The grey circles show the scaled MI values
obtained when assessing MI for a TF-target interaction across all tumours. Targets are ranked, showing those with the highest
MINDy Analysis in Breast Cancer
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The green circles represent the shift (MIshift) in the MI and values are calculated as:
MIshift ¼ MIoriginal þ ðMIoriginal  dMIÞ
Cell culture
MCF-7 human breast cancer cells were cultured in DMEM (Invitrogen) supplemented with
10% FBS and antibiotics. T47D and ZR751 human breast cancer cells were cultured in RPMI
(Invitrogen) supplemented with 10% FBS and antibiotics. HB2 mammary luminal epithelial
cells were cultured in DMEM (Invitrogen) supplemented with 10% FBS, 5 μg/ml insulin, 1 μg/
ml hydrocortisone and antibiotics. All cells were maintained at 37˚C, 5% CO2. All cell lines
were from the CRUK Cambridge Institute collection and cell line identity was confirmed by
STR genotyping.
Quantitative RT-PCR
1 μg of total RNA was reverse transcribed using the High Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems) and qRT-PCR performed using cDNA obtained from 10 ng of
total RNA. qRT-PCR was performed using an ABI 9800HT Sequence Detection System
(Applied Biosystems) with SDS software version 2.3. All primers were specific for each gene of
interest (Table 1). Amplification and detection were carried out in 384-well Optical Reaction
Plates (Applied Biosystems) with Power SYBR Green Fast 2x qRT-PCR Mastermix (Applied
Biosystems). All expression data were normalised to DGUOK expression. Primer-specificity
was confirmed at the end of each qRT-PCR run through the generation of single peaks in
melt-curve analysis. Data analysis was performed using the 2-ΔΔCT method [13].
Western immunoblotting
Cells were grown in 10 cm Petri dishes, washed in PBS and lysed on ice in RIPA buffer with
cOmplete Mini EDTA-free protease inhibitor cocktail (Roche). Resulting cell lysates were
passed through a fine-gauge syringe needle several times, centrifuged at 10,000 g for 1 minute
and left at -80˚C at least overnight. Protein samples were separated by SDS-PAGE using
4–12% Bis-Tris gels (Novex) for 2.5 hours (30 minutes at 60 V, 120 minutes at 120 V) and
transferred by electrophoresis using an iBlot (Novex) for 7 minutes onto a nitrocellulose mem-
brane (iBlot Gel Transfer Stacks; Novex). Successful transfer of protein was confirmed using
mutual information on the left, those with the lowest towards the right. The green circles mark those targets for which a
significant change in MI was observed when comparing the MI for TF|t for top 1/3 to the bottom 1/3 of all tumours ranked by the
gene expression value for M (see materials and methods for calculations). ALDH3B (B) is an example of a modulator that
reduces mutual information, ARHGEF2 (C) is a modulator able to increase TF|t similarities in expression. The inset text shows
the resulting statistics that assess whether the number of modulated targets is different from what would be expected by
chance, using two complementary tests: FET (Fisher’s Exact Test) and KS (Kolmogorov-Smirnov test). Of note, in the
examples shown the TF-target pairs with the strongest MI show the greatest modulation, resulting a in a significant KS P-value.
doi:10.1371/journal.pone.0168770.g001
Table 1. Primers used in qRT-PCR to determine mRNA expression.
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Ponceau S Solution (Sigma). Membranes were “blocked” at room temperature for 1 hour with
5% (w/v) dried milk in Tris-buffered saline (TBS) with 0.1% Tween-20 (TTBS), washed 3x
with TTBS and probed with the relevant primary antibody (anti-SPDEF, 1:200, Santa Cruz sc-
67022; anti-FOXA1, 1:1000, Abcam ab5089; anti-FGFR2, 1:200, Santa Cruz sc-122; anti-β-
actin, 1:5000, Cell Signalling) in blocking solution at 4˚C overnight. Membranes were then re-
washed with TTBS 3x and incubated with appropriate HRP-conjugated secondary antibody
(anti-rabbit, 1:10,000, Amersham; anti-goat, 1:2000, Dako) in blocking solution at room
temperature for 90 minutes. Following further washing with TTBS, blots were treated with
SuperSignal West Chemiluminescent Substrate (Thermo Scientific) and immunoreactive pro-
teins detected by exposure to film (FUJIFILM).
Transient transfection of siRNA
Cells were transfected with ON-TARGETplus SMARTpool siRNA (Dharmacon) directed
against SPDEF (L-020199-00), FOXA1 (L-010319-00), FGFR2 (L-003132-00), CCND1 (L-
003210-00), MSL3 (L-012319-02), ARHGEF2 (L-009883-00) and a control non-targeting pool
(D-001810-01) using Lipofectamine RNAiMax Reagent (Invitrogen), according to manufac-
turer’s protocol. Following addition of the transfection complexes, cells were incubated at
37˚C, 5% CO2 for 24–48 hours before experiments were performed.
Transient transfection of siRNA for proliferation assays
Proliferation assays were performed in 96-well reverse transfection (RTF) plates (Dharmacon)
and rehydration of siRNA was performed according to manufacturer’s protocol. Briefly,
lyophilised siRNA for each of the 189 modulators of SPDEF and FOXA1, identified by
MINDy, was rehydrated in the RTF plates using cell culture medium and Lipofectamine
RNAiMax Reagent (Invitrogen), and siRNA transfection complexes were allowed to form.
4000 cells per well were then added to the plates, ready for proliferation analysis. The complete
list of modulators against which siRNAs were targeted is available in S1 Table.
Proliferation assay
Cells were plated at 4000 cells per well into 96-well plates and cell numbers monitored in real
time by in vitro micro-imaging using an IncuCyte incubator (Essen BioScience), allowing for
monitoring of cell proliferation by observing cell confluence. Images were taken every three
hours and data consisted of an average of four separate images taken for each well. Assays
were performed in triplicate on three separate occasions. Statistical analysis of proliferation
data was performed using the compareGrowthCurves command in the statmod package in R
(http://CRAN.R-project.org/package=statmod). Multiple testing correction was achieved
using the Benjamini-Hochberg method.
Molecular cloning
Three repeats of the SPDEF DNA binding consensus sequence was cloned into a pLUC2CP
Luciferase Reporter Vector (kindly donated by the lab of David Neal, CRUK Cambridge Insti-
tute), following AscI/NheI digestion (AscI-(ACA GTG GTC CCG GAT TAT CGA)3-NheI), to
generate a reporter construct in which luciferase gene expression is influenced by SPDEF pro-
tein binding. The orientation and sequence of the cloned plasmid was confirmed by DNA
sequencing (GATC Biotech).
MINDy Analysis in Breast Cancer
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Luciferase reporter assay
MCF-7 cells were plated at 0.5x105 cells/well in 24-well dishes and left in complete medium
until 50–70% confluent. If required, cells were first transfected with siRNA using Lipofecta-
mine RNAiMax Reagent (Invitrogen), according to manufacturer’s protocol and left for 24
hours. Cells were then transfected with luciferase and β-galactosidase constructs together at a
concentration of 0.5 and 0.1 μg per well, respectively, using FuGENE HD Transfection
Reagent (Promega), according to manufacturer’s protocol. After 24 hours at 37˚C, 5% CO2,
cells were lysed with Reporter Lysis Buffer (Promega) and luciferase and β-galactosidase assays
were performed on a PHERAstar FS Microplate Reader (BMG LABTECH) using the appropri-
ate assay kits (Promega), according to manufacturer’s protocol. Transfection of each reporter
construct was performed in triplicate in each assay and a total of three assays were performed
on three separate days.
Code availability
The source code developed in this study is publicly available from Bioconductor in the R pack-
age RTN (http://bioconductor.org/packages/RTN/).
Results
The MINDy algorithm identifies potential modulators of breast cancer
risk TF activity
Previously, we have investigated TF involvement in modulating polygenic risk in breast can-
cer. We have identified 36 TFs whose regulons are significantly enriched for genes associated
with breast cancer risk loci (termed “risk TFs”) [14], and four of these risk TFs (ESR1, FOXA1,
GATA3 and SPDEF) have been identified as MRs of FGFR2-mediated risk in breast cancer
[4]. In this study we applied the MINDy algorithm to ESR1, FOXA1, GATA3 and SPDEF, and
their regulons. The MINDy algorithm (see materials and methods for details) was able to iden-
tify a total of 506 potential post-transcriptional modulators of ESR1, GATA3, FOXA1 and/or
SPDEF activity. Of these 506 identified genes, 212 positively modulated one or several of the
four TFs (Fig 2), 232 negatively modulated them (S1 Fig), and 62 lay in-between two or more
of the TFs (we refer to these as the “in-modulators”), i.e. they were downstream of one of the
TFs and upstream of another (S2 Fig). The vast majority of the positive and negative modula-
tors that were identified affect the activity of FOXA1, with relatively few impacting on the
activity of the other three TFs. We therefore chose to focus on FOXA1 for experimental valida-
tion of our results, and also SPDEF because it is a less well-studied, newly-identified ER+ breast
cancer risk TF.
Experimental validation and set-up
Previous studies [14] demonstrated that both FOXA1 and SPDEF are required for prolifera-
tion of ZR751 ER+ breast cancer cells. To determine the relevance of the identified modulators
we therefore examined if downregulation of the positive modulators would affect cell prolifera-
tion in a FOXA1 or SPDEF-dependent manner. We focused our analysis on positive modula-
tors since, in already rapidly proliferating cell lines, inhibition of growth might be more easily
detectable than a potential increase in proliferation. Moreover, given the dependence of ER+
cell lines on FOXA1, positive modulators would be more attractive therapeutic targets.
We first characterised SPDEF and FOXA1 expression and activity in three ER+ breast can-
cer cell lines (MCF-7, T47D and ZR751). Both SPDEF and FOXA1 mRNA and protein were
expressed in all three ER+ breast cancer cell lines, and their expression levels were significantly
MINDy Analysis in Breast Cancer
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reduced following transfection of siRNA against the TFs (Fig 3A–3C). In all three ER+ cell
lines, transfection of siRNA against SPDEF or FOXA1 also significantly reduced cell prolifera-
tion compared with transfection of a control, non-targeting siRNA sequence (Fig 3D–3F).
This suggests that proliferation of the ER+ breast cancer cell lines was dependent on SPDEF
and FOXA1 activity. In contrast, the HB2 cell line is a human mammary epithelial cell line
with hardly detectable levels of SPDEF and very low levels of FOXA1 compared with ER+
breast cancer cell lines (Fig 4A–4C), whose growth does not depend on SPDEF and FOXA1
activity (Fig 4D). We therefore used HB2 cells as controls to establish whether the activity of
the identified modulator was FOXA1 or SPDEF-dependent or occurred via a non-specific
mechanism. In order to satisfy ourselves that siRNA is able to get into the HB2 cells, transfec-
tion experiments were performed. siRNA transfection in HB2 cells was efficient, as demon-
strated by transfection of siGLO RED Transfection Indicator (Fig 4E). Also, transfection of
siRNAs directed against FGFR2 and CCND1 significantly reduced levels of mRNA for these
genes (Fig 4F) and reduced levels of FGFR2 protein (Fig 4G). Furthermore, HB2 cell prolifera-
tion was inhibited following transfection of siRNA directed against CCND1, unlike with
siRNA directed against SPDEF and FOXA1 (Fig 4H).
The following criteria were used to select a list of modulators to validate. Firstly, only posi-
tive modulators were chosen (Fig 2). Secondly, all positive modulators of SPDEF that were
Fig 2. Post-transcriptional modulators of ESR1, GATA3, FOXA1 and SPDEF identified by MINDy. The MINDy algorithm
was used to identify positive modulators, negative modulators and “in-modulators” of four TFs in ER+ breast cancer (ESR1,
GATA3, FOXA1 and SPDEF). Just the positive modulators identified by MINDy are presented here. Negative modulators and in-
modulators are presented in S1 and S2 Figs, respectively.
doi:10.1371/journal.pone.0168770.g002
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Fig 3. SPDEF and FOXA1 expression and activity in ER+ breast cancer cell lines. (A and B) Relative mRNA expression
of SPDEF (A) and FOXA1 (B) in MCF-7, T47D and ZR751 ER+ breast cancer cells following transfection with siRNA directed
against SPDEF and FOXA1, respectively. All data were normalised to DGUOK expression (n = 10, two separate experiments,
P<0.001 (***), one-way ANOVA and SNK correction, error bars = SEM). (C) Representative Western immunoblots showing
expression of SPDEF, FOXA1 and β-actin proteins in MCF-7, T47D and ZR751 ER+ human breast cancer cell lines (n = 3 for
all blots). (D-F) Growth curves for MCF-7 (D), T47D (E) and ZR751 cells (F) following transfection with siRNA directed against
SPDEF and FOXA1. Cells were transfected with scrambled, non-targeting siRNA as a control (siCTL).
doi:10.1371/journal.pone.0168770.g003
MINDy Analysis in Breast Cancer
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identified by MINDy were included (6 modulators). Thirdly, all of the in-modulators (S2 Fig)
that positively regulated SPDEF (3 modulators) were included in the analysis. Finally, the long
list of positive FOXA1 modulators was ranked by P-value and a cut-off of 0.001 was employed,
with consensus between the two cohorts. This gave a total of 189 positive post-transcriptional
modulators of SPDEF and FOXA1 to be tested (S2 Table; 6 positive modulators of SPDEF,
including one that is also a positive modulator of FOXA1 and GATA3, 180 positive modula-
tors of FOXA1, including some that are also positive modulators of ESR1 and/or GATA3, and
3 in-modulators that positively regulate SPDEF).
MINDy-identified modulators of breast cancer risk TF activity affect ER+
breast cancer cell proliferation
To test the activity of these 189 modulators, ZR751 (highest expression of SPDEF and FOXA1;
Fig 3) and HB2 cells were transfected with siRNAs targeting these modulators and cell prolifer-
ation was assayed. Statistical analysis of proliferation data was performed using the compare-
GrowthCurves command in the statmod package in R (http://CRAN.R-project.org/package=
statmod), with multiple testing correction carried out using the Benjamini-Hochberg method.
Using this statistical approach, we found that 55 modulators significantly inhibited growth of
the ZR751 cell line without affecting proliferation of the HB2 cell line (Fig 5, S3 Table, S3 Fig).
In this regard, these 55 modulators behave like the TFs they are positively modulating, in that
their reduced expression/activity results in a perturbed proliferative response, which is cell
type-specific. Our positive controls, SPDEF and FOXA1, are towards the far right of the plot
displayed in Fig 5, confirming that knocking down expression of the TFs has a large effect on
ZR751 cell proliferation compared with HB2 cell proliferation. Knocking down expression of
14 of the 189 modulators inhibited growth of both cell lines, presumably as a result of off-target
effects not associated with SPDEF/FOXA1 modulation. For example, siRNA directed against
CCND1 (encodes cyclin D1, an important cell cycle protein), was used as a control in the assay
as knocking down its expression should reduce proliferation in all cell lines, not just those
dependent on SPDEF and FOXA1 activity. Any modulator which showed a response pattern
similar to CCND1 in the assay was disregarded. Overall, we found that 53 of the FOXA1 modu-
lators had an effect on proliferation and two SPDEF modulators, MLS3 and ARHGEF2, signif-
icantly reduced proliferation specifically in ZR751 cells.
Validated modulators are frequently mutated in breast cancer
To obtain orthogonal data for the importance of the identified modulators we examined
whether the genes of the 55 validated modulators are altered in cancer. Studies with available
copy number alteration (CNA) data show that amplification of the modulator genes is very
Fig 4. SPDEF and FOXA1 expression and activity in HB2 mammary epithelial cells. (A and B) Relative
mRNA expression of SPDEF (A) and FOXA1 (B) in HB2 mammary epithelial cells. All data were normalised to
DGUOK expression (n = 10, two separate experiments, error bars = SEM). (C) Representative Western
immunoblots showing expression of SPDEF, FOXA1 and β-actin proteins in HB2 mammary epithelial cells
(n = 3 for all blots). (D) Growth curves for HB2 cells following transfection with siRNA directed against SPDEF
and FOXA1. Cells were transfected with scrambled, non-targeting siRNA as a control (siCTL). (E) Fluorescence
image for HB2 cells transfected with siGLO Red Transfection Indicator using Lipofectamine RNAiMax Reagent.
(F) Relative mRNA expression of FGFR2 and CCND1 in HB2 mammary epithelial cells following transfection
with siRNA directed against FGFR2 and CCND1, respectively. All data were normalised to DGUOK expression
(n = 10, two separate experiments, P<0.001 (***), one-way ANOVA and SNK correction, error bars = SEM).
(G) Representative Western immunoblots showing expression of FGFR2 and β-actin proteins in HB2 mammary
epithelial cells following transfection with siRNA directed against FGFR2 (n = 3 for all blots). (H) Growth curves
for HB2 cells following transfection with siRNA directed against CCND1. Cells were transfected with scrambled,
non-targeting siRNA as a control (siCTL).
doi:10.1371/journal.pone.0168770.g004
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common in breast cancer [15–17] (Fig 6A). Moreover, mutations in these genes are present in
up to 10% of the samples tested in the available studies [15–20]. Collectively, our 55 modulators
have a significantly increased frequency of alterations in comparison to both random genes and
annotated cancer-related genes for which mutations have been causally implicated in cancer
[21] (Fig 6B). These data support the functional importance of the identified modulators.
MINDy-identified modulators of SPDEF activity affect SPDEF-driven
transcription
As outlined in the introduction, modulators identified by MINDy may post-transcriptionally
and/or post-translationally modify the TF, affect its cellular localisation or turnover, form a
transcriptional complex with the TF, or compete for its DNA binding site. Ultimately, the
modulator must alter the ability of the TF to drive transcription. We tested this on the two
SPDEF modulators that affected ZR751 cell proliferation (Fig 5). Transcriptional activity was
assayed by generating SPDEF-driven luciferase reporter constructs (Fig 7A) to ask if removal
of the MINDy-identified modulators of SPDEF would alter the luciferase read-out. As a posi-
tive control in our assay we transfected the SPDEF-luciferase reporter construct into ZR751
cells and observed that luciferase luminescence was reduced by 46% when siRNA directed
against SPDEF was co-transfected (Fig 7B). Similarly, when siRNA directed against MSL3 and
ARHGEF2, two validated modulators of SPDEF, was transfected into ZR751 cells, luciferase
luminescence was reduced by 30% and 26%, respectively (Fig 7C), without having any affect
on SPDEF expression levels (Fig 7D). These two SPDEF modulators were identified by
Fig 5. Experimental validation of potential SPEDF and FOXA1 modulators. Proliferation of ZR751 and HB2 cells was assayed following transfection with
siRNA directed against modulators of SPDEF and FOXA1, identified by MINDy analysis. ZR751 cells are dependent on SPDEF and FOXA1 for proliferation
whereas HB2 cells do not require these TFs for growth. The plot shows cell proliferation, represented as % cell confluence at the time-point when cell
confluence plateaus in the non-targeting siRNA control treatment (NTC), measured using an IncuCyte imaging system (only a single time-point is represented
in the plot). The proliferation screen, which was statistically analysed using the compareGrowthCurves command in the statmod package in R (http://CRAN.
R-project.org/package=statmod), with multiple testing correction carried out using the Benjamini-Hochberg method (S3 Table, S3 Fig), identified a number of
modulators that have a consistent cell type-specific effect (55 out of 189 modulators), and these are highlighted in red on the x-axis. Control treatments are
highlighted in blue on the x-axis. The dashed lines show maximum percent cell confluence achieved with the NTC treatment for ZR751 and HB2 cells. CTL:
untransfected control; NTC: non-targeting siRNA control.
doi:10.1371/journal.pone.0168770.g005
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MINDy, and the proliferation screen (Fig 5) suggests that they are required by ZR751 cells for
growth. These data therefore show that MINDy is able to identify biologically-relevant modu-
lators of TFs that can alter the TF’s transactivational activity.
Discussion
Here we demonstrate that the MINDy algorithm is able to identify post-transcriptional modu-
lators of key TFs of ER+ breast cancer. We have found and validated novel modulators of
Fig 6. The MINDy-identified modulators of SPDEF and FOXA1 are frequently altered in breast cancer. (A)
Plot from cBioPortal for Cancer Genomics showing the alteration frequency of the 55 SPDEF and FOXA1
modulators validated in this study, from nine different breast cancer studies. (B) Mean aberration frequency
(mutations or copy number alterations) of the 55 SPDEF and FOXA1 modulators in comparison to sets of 55
random genes (empirical P<0.001; box-plot whiskers extend to the 1st and 99th percentiles of the random
distribution with 10,000 random sets). Aberration frequencies for sets of random TFs and cancer genes are also
shown.
doi:10.1371/journal.pone.0168770.g006
MINDy Analysis in Breast Cancer
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FOXA1 and SPDEF, both of which are of special interest in breast cancer. FOXA1 may be a
particularly relevant therapeutic target since cancers that have become resistant to hormone
treatment may still be dependent on FOXA1 for proliferation [22]. Also, SPDEF may be an
important regulator of cell metastasis, not just in prostate but also in breast cell lines [23]. Both
TFs also affect the risk of developing breast cancer [4] and are therefore of interest in designing
preventative strategies.
To seek experimental validation of the candidate modulators, we transfected siRNA librar-
ies directed against positive modulators into SPDEF and FOXA1-dependent and -independent
cell lines, and potential biologically-relevant modulators were identified on the basis of affect-
ing proliferation in one, but not the other cell line. Of the 189 modulators selected for study,
over a quarter (55) were shown to affect ER+ breast cancer cell growth when compared to a
cell line that does not require the TFs in order to proliferate. The primary function of 25 out of
these 55 modulators is classed as having a role in either cell cycle or transcription (GO term
analysis), supporting the idea that these modulators might affect the activity of a TF required
for cell proliferation. Validation assays based on other cellular phenotypes or specific protein
function may be able to validate additional modulators identified in our computational
analysis.
As yet, we do not understand why MINDy was able to identify such a large number of mod-
ulators of FOXA1, while only finding relatively few factors that affected ESR1, given that these
two TFs share many binding sites and target genes [22,24,25]. One possible explanation may
lie in the fact that ESR1 activity depends on the presence of estrogen, which may not be univer-
sally available within the tumour. The link between gene expression and target genes may
therefore be less strong and MINDy less able to find modulators. There may be other con-
founding factors. Regulatory processes associated with the cell cycle are largely modulated by
protein phosphorylation cascades. Such alterations, potentially leading to protein degradation,
may break the correlation of gene expression between the TF and its targets that the MINDy
algorithm relies on.
In conclusion, our analysis of the effect of potential modulators of SPDEF and FOXA1
activity in ER+ breast cancer suggests that MINDy and other such computational tools have
the power to identify valid modulators of TF activity that warrants further follow-up work. For
SPDEF we found two modulators which have the ability to reduce SPDEF-driven transcrip-
tion. MLS3 is a component of the MLS complex responsible for the majority of histone H4
acetylation at Lys16. GO annotations for this nuclear protein include chromatin organisation
and transcription. ARHGEF2 is a primarily cytoplasmic Rho/Rac guanine nucleotide exchange
factor involved in signalling by G-protein coupled receptors. Further functional follow-up
analysis of these proteins in the context of ER+ breast cancer may be warranted. Also, a large
Fig 7. MINDy-identified modulators of SPDEF activity affect SPDEF-driven transcription. (A)
Schematic depiction of the reporter construct used in the luciferase reporter assays. (B) Luciferase
luminescence in MCF-7 cells 24 hours post-transfection of reporter construct containing SPDEF binding
domains (SPDEF), normalised to β-galactosidase expression (n = 9, three separate experiments, P<0.001
(***), one-way ANOVA and SNK correction, error bars = SEM). pGL3 Basic/pGL3 Control: control luciferase
reporter vectors; Empty Luc2CP: Empty vector control; siSPDEF: SPDEF siRNA treatment. (C) Luciferase
luminescence 24 hours post-transfection of reporter construct containing SPDEF binding domains into MCF-7
cells treated with siRNA directed against SPDEF, MSL3 and ARHGEF2, normalised to β-galactosidase
expression (n = 9, three separate experiments, P<0.001 (***), one-way ANOVA and SNK correction, error
bars = SEM). CTL: untransfected control; siScrambled: non-targeting siRNA control. (D) Relative mRNA
expression of SPDEF in MCF-7 cells following transfection with siRNA directed against SPDEF, MSL3 and
ARHGEF2. All data were normalised to DGUOK expression (n = 10, two separate experiments, P<0.001
(***), one-way ANOVA and SNK correction, error bars = SEM) CTL: untransfected control; siScrambled:
non-targeting siRNA control.
doi:10.1371/journal.pone.0168770.g007
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number of FOXA1 modulators that can affect proliferation were found and future studies will
have to assess their contribution to driving the cancer phenotype.
TFs are notoriously difficult targets to drug [26]. Therefore, the availability of tools that can
accurately identify modulators of TFs, which could prove to be more tractable therapeutic tar-
gets, is very appealing.
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package in R (http://CRAN.R-project.org/package=statmod). Multiple testing correction was
achieved using the Benjamini-Hochberg method.
(PDF)
S1 Table. siRNA plate layout.
(XLS)
S2 Table. Modulator list.
(XLSX)
S3 Table. MINDy-identified modulator genes showing statistically significant impact on
proliferation of ZR751 cells compared to control.
(DOCX)
Acknowledgments
We thank the Biorepository, Bioinformatics and Research Instrumentation Core Facilities at
The CRUK Cambridge Institute for their help and expertise.
Author Contributions
Conceptualization: TMC MAAC BAJP KBM.
Formal analysis: TMC MAAC.
Funding acquisition: KBM BAJP.
Investigation: TMC MAAC.
Methodology: TMC MAAC BAJP KBM.
Software: MAAC.
Supervision: BAJP KBM.
MINDy Analysis in Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0168770 December 20, 2016 15 / 17
Validation: TMC.
Visualization: TMC MAAC KBM.
Writing – original draft: TMC MAAC BAJP KBM.
Writing – review & editing: TMC MAAC BAJP KBM.
References
1. Bansal M, Califano A (2012) Genome-wide dissection of posttranscriptional and posttranslational inter-
actions. Methods Mol Biol 786: 131–149. doi: 10.1007/978-1-61779-292-2_8 PMID: 21938624
2. Wang K, Saito M, Bisikirska BC, Alvarez MJ, Lim WK, Rajbhandari P, et al. (2009) Genome-wide identi-
fication of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol
27: 829–839. doi: 10.1038/nbt.1563 PMID: 19741643
3. Campbell TM, Castro MA, de Santiago I, Fletcher MN, Halim S, Prathalingam R, et al. (2016) FGFR2
risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness. Carcinogenesis 37:
741–750. doi: 10.1093/carcin/bgw065 PMID: 27236187
4. Fletcher MN, Castro MA, Wang X, de Santiago I, O’Reilly M, Chin SF, et al. (2013) Master regulators of
FGFR2 signalling and breast cancer risk. Nat Commun 4: 2464. doi: 10.1038/ncomms3464 PMID:
24043118
5. Jozwik KM, Carroll JS (2012) Pioneer factors in hormone-dependent cancers. Nat Rev Cancer 12:
381–385. doi: 10.1038/nrc3263 PMID: 22555282
6. Takaku M, Grimm SA, Wade PA (2015) GATA3 in Breast Cancer: Tumor Suppressor or Oncogene?
Gene Expr 16: 163–168. doi: 10.3727/105221615X14399878166113 PMID: 26637396
7. Steffan JJ, Koul HK (2011) Prostate derived ETS factor (PDEF): a putative tumor metastasis suppres-
sor. Cancer Lett 310: 109–117. doi: 10.1016/j.canlet.2011.06.011 PMID: 21764212
8. Sood AK, Kim H, Geradts J (2012) PDEF in prostate cancer. Prostate 72: 592–596. doi: 10.1002/pros.
21461 PMID: 21796651
9. Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, et al. (2007) Expres-
sion characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progres-
sion. Hum Pathol 38: 1628–1638. doi: 10.1016/j.humpath.2007.03.010 PMID: 17521701
10. Turcotte S, Forget MA, Beauseigle D, Nassif E, Lapointe R (2007) Prostate-derived Ets transcription
factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive
breast cancer. Neoplasia 9: 788–796. PMID: 17971898
11. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK (2003) Pdef expression in human
breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 63: 4626–
4631. PMID: 12907642
12. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, et al. (2000) PDEF, a novel prostate
epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-
specific antigen gene expression. J Biol Chem 275: 1216–1225. PMID: 10625666
13. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative
PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408. doi: 10.1006/meth.2001.1262 PMID:
11846609
14. Castro MA, de Santiago I, Campbell TM, Vaughn C, Hickey TE, Ross E, et al. (2016) Regulators of
genetic risk of breast cancer identified by integrative network analysis. Nature Genetics 48: 12–21. doi:
10.1038/ng.3458 PMID: 26618344
15. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70. doi: 10.1038/
nature11412 PMID: 23000897
16. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. (2015) Comprehensive Molec-
ular Portraits of Invasive Lobular Breast Cancer. Cell 163: 506–519. doi: 10.1016/j.cell.2015.09.033
PMID: 26451490
17. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, et al. (2015) Dynamics of genomic clones in breast
cancer patient xenografts at single-cell resolution. Nature 518: 422–426. doi: 10.1038/nature13952
PMID: 25470049
18. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. (2012) Sequence
analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405–409. doi: 10.
1038/nature11154 PMID: 22722202
MINDy Analysis in Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0168770 December 20, 2016 16 / 17
19. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. (2012) The clonal and mutational evolution
spectrum of primary triple-negative breast cancers. Nature 486: 395–399. doi: 10.1038/nature10933
PMID: 22495314
20. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. (2012) The landscape
of cancer genes and mutational processes in breast cancer. Nature 486: 400–404. doi: 10.1038/
nature11017 PMID: 22722201
21. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. (2015) COSMIC: explor-
ing the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43: D805–811.
doi: 10.1093/nar/gku1075 PMID: 25355519
22. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS (2011) FOXA1 is a key determinant of
estrogen receptor function and endocrine response. Nat Genet 43: 27–33. doi: 10.1038/ng.730 PMID:
21151129
23. Steffan JJ, Koul S, Meacham RB, Koul HK (2012) The transcription factor SPDEF suppresses prostate
tumor metastasis. J Biol Chem 287: 29968–29978. doi: 10.1074/jbc.M112.379396 PMID: 22761428
24. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, et al. (2006) Genome-wide analysis
of estrogen receptor binding sites. Nat Genet 38: 1289–1297. doi: 10.1038/ng1901 PMID: 17013392
25. Welboren WJ, Stunnenberg HG, Sweep FC, Span PN (2007) Identifying estrogen receptor target
genes. Mol Oncol 1: 138–143. doi: 10.1016/j.molonc.2007.04.001 PMID: 19383291
26. Verdine GL, Walensky LD (2007) The challenge of drugging undruggable targets in cancer: lessons
learned from targeting BCL-2 family members. Clin Cancer Res 13: 7264–7270. doi: 10.1158/1078-
0432.CCR-07-2184 PMID: 18094406
MINDy Analysis in Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0168770 December 20, 2016 17 / 17
